A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2012
At a glance
- Drugs RAV 12 (Primary)
- Indications Adenocarcinoma
- Focus Adverse reactions
- 19 Apr 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 19 Apr 2012 Company added in association field as reported by ClinicalTrials.gov.
- 19 Apr 2012 Actual end date (1 May 2008) added as reported by ClinicalTrials.gov.